

DAFTAR PUSTAKA

1. Ferlay J *et al.* Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://Gco.Iarc.Who.Int/Today>, Accessed [8 April 2025].
2. Health Commission of the PRC, N. National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version). *Chin J Cancer Res.* 2022 Jun 30; 34: 131–150. Available from: doi: 10.21147/j.issn.1000-9604.2022.03.01.
3. Bray, F. *et al.* Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2024 May-Jun; 74: 229–263. Available from: doi: 10.3322/caac.21834.
4. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia 2014. Kanker di Indonesia tahun 2014 : Data Histopatologik. 2014. Jakarta Direktorat Jendral Pelayanan Medik Kementerian Kesehatan RI, Yayasan Kanker Indonesia, Jakarta.
5. Baloch, Z. W. *et al.* Papillary thyroid carcinoma. In: WHO classification of tumours editorial board. Endocrine and neuroendocrine tumours: International Agency for Research on Cancer; 5th Edition. Lyon (France); 2025 (cited 2025 Mar 10). Available from: <https://tumourclassification.iarc.who.int/chapters/53>.
6. Rosai, J., Tallini, G. Thyroid gland. In: Rosai & Ackerman's surgical pathology tenth edition. Elsevier; 2011. p 504–514.
7. Kitahara, C. M. & Schneider, A. B. Epidemiology of thyroid cancer. *Cancer Epidemiol Biomarkers Prev.* 2022 Jul 1; 31: 1284–1297. Available from doi: 10.1158/1055-9965.EPI-21-1440.
8. Khan, A. Surgical pathology of endocrine and neuroendocrine tumors; 2009. Available from: <http://www.springer.com/springer/series/7632>.
9. Nath, M. C. & Erickson, L. A. Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar, and solid. *Adv Anat Pathol.* 2018 May; 25: 172-179. Available from: doi: 10.1097/PAP.000000000000184.
10. Coca-Pelaz, A., Jatin P. Shah, Juan C. Hernandez-Prer, Ronald A. Ghossein & Juan P. Rodrigo. Papillary thyroid cancer aggressive variants and impact on management a narrative review. *Adv Ther.* 2020 Jul; 37: 3112-3128. Available from: doi: 10.1007/s12325-020-01391-1.
11. Filetti, S. *et al.* Thyroid cancer: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2019 Dec 1; 30: 1856–1883. Available from: doi: 10.1093/annonc/mdz400.



12. Póvoa, A. A. *et al.* Clinicopathological features as prognostic predictors of poor outcome in papillary thyroid carcinoma. *Cancers (Basel)*. 2020 Oct 29; 12: 1–16. Available from: doi: 10.3390/cancers12113186.
13. Sun, J. H. *et al.* Evaluation of recurrence risk in patients with papillary thyroid cancer through tumor-node-metastasis staging: A single-center observational study in Taiwan. *Biomed J*. 2022 Dec; 45: 923–930. Available from: doi: 10.1016/j.bj.2021.11.009.
14. Haugen, B. R. *et al.* 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid*. 2016 Jan; 26: 1–133. Available from: DOI: 10.1089/thy.2015.0020
15. Nakamura, M. *et al.* E-cadherin expression and cell proliferation in the primary tumor and metastatic lymph nodes of papillary thyroid microcarcinoma. *Mol Clin Oncol*. 2014 Mar; 2: 226–232. Available from: doi: 10.3892/mco.2013.220.
16. Aghajani, M. J. *et al.* Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer. *Endocr Connect*. 2020 Oct; 9: 1028–1041. Available from: doi: 10.1530/EC-20-0268.
17. Zhu, X., Wang, X., Gong, Y. & Deng, J. E-cadherin on epithelial–mesenchymal transition in thyroid cancer. *Cancer Cell Int*. 2021 Dec 20; 21: 695. Available from <https://doi.org/10.1186/s12935-021-02344-6>.
18. Zhou, C., Yang, C. & Chong, D. E-cadherin expression is associated with susceptibility and clinicopathological characteristics of thyroid cancer: A PRISMA-compliant meta-analysis. *Medicine (Baltimore)*. 2019 Jul; 98: e16187. Available from: <https://doi.org/10.1097/MD.00000000000016187>.
19. Zhou, Y. *et al.* Tumor biomarkers for diagnosis, prognosis and targeted therapy. *Signal Transduct Target Ther*. 2024 May 20; 9: 132. Available from <https://doi.org/10.1038/s41392-024-01823-2>.
20. Corina Andriescu, E., Căruntu, I., Eliza Giușcă, S., Lozneau, L. & Gabriela Ciobanu Apostol, D. Prognostic significance of cell-adhesion molecules in histological variants of papillary thyroid carcinoma. *Rom J Morphol Embryol*. 2018; 59: 721–727.
21. Mariana Calangiu, C. *et al.* The expression of CK19, vimentin and E-cadherin in differentiated thyroid carcinomas. *Rom J Morphol Embryol*. 2014; 55: 919–925.
22. Roosandris, P., Kusumastuti, E., Kurniasari, N. Perbedaan ekspresi hbme-1 dan e-cadherin pada nodular hiperplasia, karsinoma papiler, dan folikular tiroid.

- Indonesian Journal of Cancer*. 2017; 11. Available from: doi: 10.33371/ijoc.v11i4.530.
23. Shank, J. B., Are, C. & Wenos, C. D. Thyroid cancer: global burden and trends. *Indian J Surg Oncol*. 2022 Mar; 13: 40–45. Available from doi: 10.1007/s13193-021-01429-y.
24. Lam, Alfred K., ed. Papillary thyroid carcinoma methods and protocols. New York, NY: Humana Press, 2022. Available from: <http://www.springer.com/series/7651>.
25. Mahmud Gauhar, T. Papillary thyroid carcinoma. *J Thyroid Disord Ther*. 2014; 03. Available from: doi:10.4172/2167-7948.1000141.
26. Drozd, V., Branovan, D. I. & Reiners, C. Increasing incidence of thyroid carcinoma: risk factors and seeking approaches for primary prevention. *Int J Thyroidol*. 2020 Nov 30; 13: 95–110. Available from: <https://doi.org/10.11106/ijt.2020.13.2.95>.
27. Hu, M.-J., Zhao, H.-H. & Guo, A.-L. Body mass index and weight gain after middle adulthood are associated with risk of papillary thyroid cancer: A case–control study. *Cancer Epidemiol*. 2021 Dec; 75: 102039. Available from: doi: 10.1016/j.canep.2021.102039.
28. Pellegriti, G., Frasca, F., Regalbuto, C., Squatrito, S. & Vigneri, R. Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. *J Cancer Epidemiol* 2013 May 7; 965212. Available from: <https://doi.org/10.1155/2013/965212>.
29. Thompson, L. & Wenig, B. Diagnostic pathology: head and neck, second edition. Philadelphia: Elsevier Inc.; 2016.
30. Kumar, V., Abbas, A. K. & Aster, J. C. Robbins basic pathology. 4th ed. Philadelphia: Elsevier Saunders; 2018.
31. Prete, A. *et al*. Update on fundamental mechanisms of thyroid cancer. *Front Endocrinol (Lausanne)*. 2020 Mar 13; 11: 102. Available from: <https://doi.org/10.3389/fendo.2020.00102>.
32. De Leo, A. *et al*. Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance. *Virchows Arch*. 2024 Feb;484: 289–319 Available from: <https://doi.org/10.1007/s00428-023-03713-4>.
33. Scholfield, D. W. *et al*. Diffuse sclerosing papillary thyroid carcinoma: clinicopathological characteristics and prognostic implications compared with

classic and tall cell papillary thyroid cancer. *Ann Surg Oncol*. 2023 Aug; 30: 4761– 4770. Available from: doi: 10.1245/s10434-023-13589-y.

34. Chereau, N. *et al*. Diffuse sclerosing variant of papillary thyroid carcinoma is associated with aggressive histopathological features and a poor outcome: Results of a large multicentric study. *J Clin Endocrinol Metab*. 2016 Dec; 101: 4603–4610. Available from: doi: 10.1210/jc.2016-2341.
35. Ohashi, R. Solid variant of papillary thyroid carcinoma: An under-recognized entity. *Endocr J*. 2020 Mar; 67: 241–248. Available from: <https://doi.org/10.1507/endocrj.EJ19-0414>.
36. Nose, V. *Diagnostic pathology: endocrine*, 2nd edition. Salt Lake City: Elsevier Inc.; 2018.
37. Lubitz, C. C. *et al*. Hobnail variant of papillary thyroid carcinoma: An institutional case series and molecular profile. *Thyroid*. 2014 Jun; 24: 958–965. Available from: doi: 10.1089/thy.2013.0573.
38. Asioli, S. *et al*. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. a clinicopathologic, immunohistochemical, and molecular study of eight cases. *Am J Surg Pathol*. 2010 January; 34: 44-52. Available from: doi: 10.1097/PAS.0b013e3181c46677.
39. Faten Limaïem, Anis Rehman & Thomas Mazzoni. Papillary thyroid carcinoma. *NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health*. 2025.
40. Pisanu, A., Deplano, D., Reccia, I., Porceddu, G. & Uccheddu, A. Encapsulated papillary thyroid carcinoma: Is it a distinctive clinical entity with low-grademalignancy? *J Endocrinol Invest*. 2013 Feb; 36: 78–83. Available from: doi: 10.3275/8241.
41. Sharma, A. K. *et al*. Encapsulated follicular variant of papillary thyroid carcinoma: a review on surgical treatment. *Indian J Otolaryngol Head Neck Surg*. 2022 Dec; 74: 6384–6390. Available from: doi: 10.1007/s12070-022-03107-z.
42. Kumar, T., Nigam, J. S., Tewari, P. & Jha, C. K. Warthin-like variant of papillary thyroid carcinoma: an uncommon variant. *Cureus*. 2020 Dec 28; 12: e12350. Available from: doi:10.7759/cureus.12350.
43. Arrangoiz, R. *et al*. Current understanding of papillary thyroid carcinoma. *Int J Otolaryngol Head Neck Surg*. 2021 May; 10: 184–221. Available from: DOI: 10.4236/ijohns.2021.103019

44. Juhlin, C. C. & Höög, A. Clear cell variant of papillary thyroid carcinoma with associated anaplastic thyroid carcinoma: description of an extraordinary case. *Int J Surg Pathol.* 2019 Sep; 27: 658–663. Available from: doi: 10.1177/1066896919837678.
45. Parkhi, M. *et al.* Papillary thyroid carcinoma with nodular fasciitis-like stroma: A rare variant. *Autops Case Rep.* 2021 August 20; 11: e2021320. Available from: doi: 10.4322/acr.2021.320.
46. Khan, S., Hassan, M. J., Hameed, S. & Jetley, S. Spindle cell variant of papillary thyroid carcinoma: A diagnostic challenge - A rare case report with brief review of literature. *J Cancer Res Ther.* 2023 Jan 1; 19: S881–S885. Available from: doi: 10.4103/jcrt.jcrt_66_23.
47. Papi, G., Corrado, S. & LiVolsi, V. A. Primary spindle cell lesions of the thyroid gland: an overview. *Am J Clin Pathol.* 2006 Jun; 125: S95–S123. Available from: doi: 10.1309/4DQW6RQX3C6KRX1J.
48. Ma, X., Xia, C., Liu, H. & Zhu, W. Case report primary thyroid spindle cell tumors: spindle cell variant of papillary thyroid carcinoma? *Int J Clin Exp Pathol.* 2015 Oct 1; 8: 13528–31.
49. Araque, K. A., Gubbi, S. & Klubo-Gwiedzinska, J. Updates on the management of thyroid cancer. *Horm Metab Res.* 2020 Aug; 52: 562–577. Available from: <https://doi.org/10.1055/a-1089-7870>.
50. Girardi, F. M., Barra, M. B. & Zettler, C. G. Variants of papillary thyroid carcinoma: Association with histopathological prognostic factors. *Braz J Otorhinolaryngol.* 2013 Nov-Dec; 79: 738–744. Available from: doi: 10.5935/1808-8694.20130135.
51. Lamartina, L. *et al.* 8th edition of the AJCC/TNM staging system of thyroid cancer: What to expect (ITCO#2). *Endocr Relat Cancer.* 2018 Mar; 25: L7–L11 Available from: <https://doi.org/10.1530/ERC-17-0453>.
52. Moslehi, M. *et al.* Differentiated thyroid cancer in Iran - Initial observations, histological features, management of the disease, and tumor recurrence: A review of 1689 cases. *Indian J Cancer.* 2016 Apr-Jun; 53: 261–264. Available from: doi: 10.4103/0019-509X.197727.
53. Wheelock, M. J., Shintani, Y., Maeda, M., Fukumoto, Y. & Johnson, K. R. Cadherin switching. *J Cell Sci.* 2008 Mar 15; 121: 727–735. Available from: <https://doi.org/10.1242/jcs.000455>.

54. Zhu, X., Wang, X., Gong, Y. & Deng, J. E-cadherin on epithelial–mesenchymal transition in thyroid cancer. *Cancer Cell Int.* 2021 Dec 20; 21: 695. Available from: <https://doi.org/10.1186/s12935-021-02344-6>.
55. Wong, S. H. M., Fang, C. M., Chuah, L. H., Leong, C. O. & Ngai, S. C. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. *Crit Rev Oncol Hematol.* 2018 Jan; 121: 11–22. Available from: <https://doi.org/10.1016/j.critrevonc.2017.11.010>.
56. Huang, H., Wright, S., Zhang, J. & Brekken, R. A. Getting a grip on adhesion: Cadherin switching and collagen signaling. *Biochim Biophys Acta Mol Cell Res.* 2019 Nov; 1866: 118472. Available from: <https://doi.org/10.1016/j.bbamcr.2019.04.002>.
57. Venhuizen, J. H., Jacobs, F. J. C., Span, P. N. & Zegers, M. M. P120 and E-cadherin: Double-edged swords in tumor metastasis. *Semin Cancer Biol.* 2020 Feb; 60: 107–120. Available from: <https://doi.org/10.1016/j.semcancer.2019.07.020>.
58. Loh, C. Y. *et al.* The e-cadherin and n-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. *Cells.* 2019 Sep 20; 8: 1118. Available from: <https://doi.org/10.3390/cells8101118>.
59. Maeda, M., Johnson, K. R. & Wheelock, M. J. Cadherin switching: Essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. *J Cell Sci.* 2005 Mar 1; 118: 873–887. Available from: doi: 10.1242/jcs.01634.
60. Ali, K. M. *et al.* Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer. *Ann Diagn Pathol.* 2019 Jun; 40: 59–65. Available from: doi: 10.1016/j.anndiagpath.2019.04.005.
61. Sheikh-Ahmad, M. *et al.* The correlation between proliferative immunohistochemical markers and papillary thyroid carcinoma aggressiveness. *Medicina (Kaunas).* 2023 Jan 4; 59: 110. Available from: doi: 10.3390/medicina59010110.
62. Ivanova, K., Ananiev, J., Aleksandrova, E., Ignatova, M. M. & Gulubova, M. Expression of E-Cadherin/beta-catenin in epithelial carcinomas of the thyroid gland. *Open Access Maced J Med Sci.* 2017 Mar 22; 5: 155–159. Available from: doi: 10.3889/oamjms.2017.043.
63. Lou, Y. *et al.* Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. *Clin Cancer Res.* 2016 Jul 15; 14: 3630–3642. Available from: doi: 10.1158/1078-0432.CCR-15-1434.

64. Harahap, A. S. *et al.* Lessons learned from the first 2 years of experience with thyroid core needle biopsy at an Indonesian national referral hospital. *J Pathol Transl Med.* 2025 May; 59: 149–160. Available from: doi: 10.4132/jptm.2025.02.19.
65. Na, D. G. *et al.* Core needle biopsy of the thyroid: 2016 consensus statement and recommendations from Korean society of thyroid radiology. *Korean J Radiol.* 2017 Jan-Feb; 18: 217–237. Available from: <https://doi.org/10.3348/kjr.2017.18.1.217>.
66. Fauziyah, R. N. Sampling dan besar sampel bidang kesehatan masyarakat dan klinis. Bandung: Politeknik Kesehatan Kemenkes Bandung, 2019. p 23.
67. Zhao, L. *et al.* Concomitant high expression of BRAFV600E, P-cadherin and cadherin 6 is associated with high TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma. *Clin Endocrinol (Oxf).* 2016 May; 84: 748–755. Available from: doi: 10.1111/cen.12878.
68. Harahap, A. S. *et al.* Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS mutational status, and clinicopathological characteristics of papillary thyroid carcinoma in Indonesian national referral hospital. *Appl Clin Genet.* 2023 May 25; 16: 99–110. Available from: doi: 10.2147/TACG.S412364.
69. Kim, Y. *et al.* Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma. *J Surg Oncol.* 2020 Oct; 122: 906–913. Available from: doi: 10.1002/jso.26090.
70. Gajowiec, A. *et al.* Is male sex a prognostic factor in papillary thyroid cancer? *J Clin Med.* 2021 May 31; 10: 2438. Available from: doi: 10.3390/jcm10112438.
71. Du, L. *et al.* Epidemiology of thyroid cancer: incidence and mortality in China, 2015. *Front Oncol.* 2020 Nov 10; 10: 1702. Available from: doi: 10.3389/fonc.2020.01702.
72. Jalali-Nadhousan, M. *et al.* Expression of estrogen and progesterone receptors in papillary thyroid carcinoma. *Caspian J Intern Med.* 2016; 7: 183-187.
73. Adeniran, A. J. *et al.* Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. *Am J Surg Pathol.* 2006 Feb; 30: 216-222. Available from: doi: 10.1097/01.pas.0000176432.73455.1b.
74. Fang, Y. *et al.* Genetic and clinical profiles of 160 papillary thyroid cancers with lateral neck lymph node metastasis. *Front Oncol.* 2023 Jan 12; 12: 1057532. Available from: doi: 10.3389/fonc.2022.1057532.

75. Sudarmanto, A. M., Prajoko, Y. W., Istiadi, H. & Yudhanto, E. Profile of thyroid cancer at dr. Kariadi general hospital semarang in 2020. *Indonesian Journal of Cancer*. 2024; 18: 16–20. Available from: doi: 10.33371/ijoc.v18i1.1017.
76. Rivera, M. *et al.* Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). *Thyroid*. 2009 Feb; 19: 119-127. Available from: doi: 10.1089/thy.2008.0303.
77. Ertek, S., Yilmaz, N.C., Cicero, A.F. *et al.* Increasing diagnosis of thyroid papillary carcinoma follicular variant in south-east anatolian region: comparison of characteristics of classical papillary and follicular variant thyroid cancers. *Endocr Pathol*. 2012 June 19; 23: 157–160. Available from: <https://doi.org/10.1007/s12022-012-9216-9>.
78. Jung, C. K., Bychkov, A. & Kakudo, K. Update from the 2022 world health organization classification of thyroid tumors: a standardized diagnostic approach. *Endocrinol Metab (Seoul)*. 2022 Oct; 37: 703–718. Available from: <https://doi.org/10.3803/EnM.2022.1553>.
79. Li C, Lee KC, Schneider EB & Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta- analysis. *J Clin Endocrinol Metab*. 2012 Dec; 97: 4559–70. Available from: doi: 10.1210/jc.2012-2104.
80. Slowinska-Klencka, D., Sporny, S., Stasikowska-Kanicka, O., Popowicz, B. & Klencki, M. E-cadherin expression is more associated with histopathological type of thyroid cancer than with the metastatic potential of tumors. *Folia Histochem Cytobiol*. 2012; 50: 519–526. Available from: doi: 10.5603/20322.
81. Baquero, P. *et al.* V600EBRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism. *Cancer Lett*. 2013 July 10; 335: 232–241. Available from: doi: 10.1016/j.canlet.2013.02.033.
82. Mitchell, B. *et al.* Original article braf and epithelial-mesenchymal transition in papillary thyroid carcinoma-challenging the roles of snail and e-cadherin?. *Am J Transl Res*. 2016 Nov 15; 8: 5076-5086. Available from: PMID: 27904709.